IDiyas

For the Inventor, By the Inventor

Littleton, MA, United States of America

Martin Youngjin Pettersson

USPTO Granted Patents = 13 

 

 

Average Co-Inventor Count = 9.9

ph-index = 3

Forward Citations = 22(Granted Patents)


Location History:

  • Waterford, CT (US) (2014)
  • Littleton, MA (US) (2014 - 2023)

Company Filing History:

goldMedal13 out of 4,455 
 
Pfizer Corporation
 patents

Years Active: 2014-2025

Loading Chart...
Loading Chart...
Loading Chart...
13 patents (USPTO):
1. 12358897 - Compounds and method of treating COVID-19 (2025-07-15),
2. 11541034 - Nitrile-containing antiviral compounds (2023-01-03),
3. 11351149 - Nitrile-containing antiviral compounds (2022-06-07),
4. 11312713 - Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors (2022-04-26),
5. 11203594 - Anti-proliferative agents for treating PAH (2021-12-21),
6. 11161844 - Cyclic substituted imidazo[4,5-c]quinoline derivatives (2021-11-02),
7. 10039753 - Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors (2018-08-07),
8. 9765073 - Cyclopropabenzofuranyl pyridopyrazinediones (2017-09-19),
9. 9751877 - Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders (2017-09-05),
10. 9193726 - Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders (2015-11-24),
11. 9067934 - Bicyclic pyridinones (2015-06-30),
12. 8916564 - Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders (2014-12-23),
13. 8697673 - Bicyclic pyridinones (2014-04-15),

Title: Inventor Spotlight: Martin Youngjin Pettersson

Introduction

Martin Youngjin Pettersson is a notable inventor based in Littleton, Massachusetts, with an impressive portfolio of 13 patents. His work primarily focuses on pharmaceutical compounds and innovative methods to combat viral infections, particularly in the context of the global COVID-19 pandemic.

Latest Patents

Among his latest contributions to science and medicine are two significant patents related to the treatment of COVID-19. The first patent, titled "Compounds and method of treating COVID-19," describes compounds of a specific formula designed to inhibit or prevent the replication of the SARS-CoV-2 virus. This invention encompasses pharmaceutical compositions that leverage these compounds, aiming for effective treatment options for patients afflicted with the virus.

The second patent, "Nitrile-containing antiviral compounds," expands on this work by detailing additional compounds capable of treating coronavirus infections, including COVID-19. Similar to his first patent, it focuses on administering therapeutically effective amounts of these compounds to patients, enhancing the arsenal of treatments available against viral outbreaks.

Career Highlights

Martin currently works at Pfizer Corporation, a leading pharmaceutical company known for its innovative approaches to healthcare. His role at Pfizer allows him to be at the forefront of medical advancements, particularly in developing new therapeutic solutions during global health crises.

Collaborations

Throughout his career, Martin has collaborated with several talented individuals in his field. Notable coworkers include Patrick Robert Verhoest and Antonia Friederike Stepan, who contribute their expertise alongside Martin to drive innovative research and development efforts within Pfizer Corporation.

Conclusion

Martin Youngjin Pettersson exemplifies the drive for innovation that characterizes the pharmaceutical industry today. Through his inventive contributions and collaborations, he continues to make significant strides in the fight against COVID-19 and other viral infections, showcasing the crucial role of inventors in advancing public health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…